PAIN
Volume 151, Issue 3 , Pages 617-624, December 2010

A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain

  • Russell K. Portenoy

      Affiliations

    • Beth Israel Medical Center, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Pain Medicine and Palliative Care, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA. Tel.: +1 (212) 844 1505; fax: +1 (212) 844 1503.
  • ,
  • Allen W. Burton

      Affiliations

    • The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
  • ,
  • Nashat Gabrail

      Affiliations

    • Gabrail Cancer Center, Canton, OH, USA
  • ,
  • Donald Taylor

      Affiliations

    • Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA
  • ,
  • on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group

Received 20 November 2009; received in revised form 26 July 2010; accepted 27 July 2010. published online 27 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0304-3959(10)00450-1

doi:10.1016/j.pain.2010.07.028

Refers to article:

  • Fentanyl for breakthrough cancer pain – what’s new? , 03 September 2010

    Nora M. Hagelberg, Klaus T. Olkkola
    PAIN December 2010 (Vol. 151, Issue 3, Pages 565-566)

PAIN
Volume 151, Issue 3 , Pages 617-624, December 2010